CLSI MM24

This guideline provides a framework for facilitating consistency in reporting genotypes and bacterial, viral, and fungal strain typing and will assist laboratories that perform these studies and the professionals applying the results. Its purpose is to present not only the technologies used but also the criteria to be considered for design, verification, validation, and determination of clinical utility of such testing. These technologies are now used in many different contexts, including:
Clinical care settings
Public health investigations, particularly of emerging infections
Food and pharmaceutical industries
Environmental analyses in the clinical setting
Regulatory agencies
This guideline is intended for manufacturers or laboratories that develop assays, laboratories that perform assays, clinicians who use the results to diagnose or manage patients, and agencies that regulate their use. This guideline:
Is not intended for use by research laboratories
Is not intended to provide manufacturing guidelines
Does not discuss the development of standard reference materials for QC use
It is recommended that this guideline be used in conjunction with CLSI documents MM03, MM06, MM09, MM12, MM13, MM14, MM17, MM18, and MM22.